FCCC CAP-IT Center has two projects and one administrative supplement award.
Project 1 (entering at Target Validation) focuses on the development of a newly identified agent that refolds mutant p53. Its ability to target the TP53 mutations associated with Li- Fraumeni Syndrome and inhibit precancerous lesions in a setting of mutant p53 will be evaluated. (For additional information, please visit NIH RePORTER)
Project 2 (entering at Agent Identification & Screening) uniquely targets the initiated pancreatic stroma as a strategy for early interception in the formation of pancreatic cancer. A neutralizing antibody against the stromal protein Netrin G1, that can revert fibroblasts to a tumor-suppressive phenotype, has been discovered. Antibodies with improved potency will be identified and tested in vivo for their ability to intercept the progression of pancreatic intraepithelial neoplasia. (For additional information, please visit NIH RePORTER)
In this supplement, the focus will be on conducting proof-of-principle studies to assess the effectiveness of DNA Polymerase Theta (Polθ) as a target for preventing BRCA1-associated cancers with the aim to evaluate Brca1 cancer initiation and Polq gene mutations. These preliminary studies will determine whether Polθ is an effective target for the interception and lay the groundwork for future studies using small molecule Polθ inhibitors. (For additional information, please visit NIH RePORTER)
